Medicines for Malaria Venture and Drugs for Neglected Diseases initiative explore the advantages of multiple ACTs for malaria and how to prolong their usefulness, co-authored by George Jagoe, Adam Aspinall and Elizabeth Poll.
As little as 10 years ago, owing to drug resistance, a clinician treating a patient for malaria would be routinely confronted with a terrible dilemma: ‘Will the drug I prescribe actually cure my patient?’ Between 1999 and 2002, rates of resistance to chloroquine and sulfadoxine-pyrimethamine (SP) in excess of 90% and up to 60%, respectively, were being reported in parts of East Africa. This dire situation continued until World Health Organization’s (WHO) prequalification of the first artemether-lumefantrine (AL) artemisinin combination therapy (ACT) in 2004, followed by growing support from donors for the large-scale introduction of ACTs. By 2005, 40 countries had adopted ACT as either first or second-line therapy and their distribution broke through the 10 million treatment mark and steadily increased over the next eight years, spurred on by the development of new fixed-dose combinations.
By 2012, 79 countries and territories had adopted ACT as first-line treatment for uncomplicated malaria....
Download the full article [PDF: 13Mb, 3 pages]
View this issue of Africa Health on the Africa Health website.
This article is co-authored by Adam Aspinall (MMV), Graciela Diap (DNDi), George Jagoe (MMV), Jean-René Kiechel (DNDi) and Elizabeth Poll (MMV).